Your browser doesn't support javascript.
COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
Alonso, Ricardo; Silva, Berenice; Garcea, Orlando; Diaz, Patricio E Correa; Dos Passos, Giordani Rodrigues; Navarro, Deyanira A Ramirez; Valle, Luis A Garcia; Salinas, Luis C Rodriguez; Negrotto, Laura; Luetic, Geraldine; Tkachuk, Verónica A; Míguez, Jimena; de Bedoya, Fernando Hamuy Diaz; Goiry, Lorna Galleguillos; Sánchez, Nicia E Ramírez; Burgos, Marcos; Steinberg, Judith; Balbuena, Maria E; Alvarez, Priscilla Monterrey; López, Pablo A; Ysrraelit, María C; León, Rosalba A; Cohen, Aron Benzadon; Gracia, Fernando; Molina, Omaira; Casas, Magdalena; Deri, Norma H; Pappolla, Agustín; Patrucco, Liliana; Cristiano, Edgardo; Tavolini, Dario; Nadur, Debora; Granda, Ana M Toral; Weiser, Roberto; Cassará, Fátima Pagani; Sinay, Vladimiro; Rodríguez, Claudia Cárcamo; Lazaro, Luciana G; Menichini, María L; Piedrabuena, Raúl; Escobar, Geraldine Orozco; Carrá, Adriana; Chertcoff, Anibal; Pujols, Biany Santos; Vrech, Carlos; Tarulla, Adriana; Carvajal, René; Mainella, Carolina; Becker, Jefferson; Peeters, Liesbet M.
  • Alonso R; Centro Universitario de Esclerosis Múltiple. Hospital Ramos Mejía, Buenos Aires, Argentina; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina.
  • Silva B; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina.
  • Garcea O; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina.
  • Diaz PEC; Hospital Carlos Andrade Maín, Ecuador.
  • Dos Passos GR; Hospital São Lucas - Pontifícia Universidade Católica do Rio Grande do Sul, Brazil.
  • Navarro DAR; Hospital Docente Padre Billini, República Dominicana.
  • Valle LAG; Hospital Militar Escuela Managua, Nicaragua.
  • Salinas LCR; Instituto Hondureño De Seguridad Social, Honduras.
  • Negrotto L; FLENI, Buenos Aires, Argentina.
  • Luetic G; Instituto de Neurociencias de Rosario, Argentina.
  • Tkachuk VA; Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina.
  • Míguez J; Hospital Italiano de Buenos Aires, Argentina.
  • de Bedoya FHD; Departamento de Neurologia, Hospital IMT, Paraguay; Departamento de Neurologia de Diagnóstico Codas Thompson, Paraguay.
  • Goiry LG; Clínica Alemana de Santiago, Chile.
  • Sánchez NER; Hospital Dr. Mario C. Rivas de San Pedro Sula, Honduras.
  • Burgos M; Hospital San Bernardo, Salta, Argentina.
  • Steinberg J; Hospital Británico de Buenos Aires, Argentina.
  • Balbuena ME; Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina.
  • Alvarez PM; Hospital San Rafael, Costa Rica.
  • López PA; Hospital Alemán de Buenos Aires, Argentina.
  • Ysrraelit MC; FLENI, Buenos Aires, Argentina.
  • León RA; Private practice, Venezuela.
  • Cohen AB; MD. Complejo Hospitalario CSS, Panamá.
  • Gracia F; Hospital Santo Tomas, Panamá.
  • Molina O; Policlinica Maracaibo, Venezuela.
  • Casas M; Hospital J. M. Ramos Mejia.
  • Deri NH; Diabaid, Buenos Aires, Argentina.
  • Pappolla A; Hospital Italiano de Buenos Aires, Argentina.
  • Patrucco L; Hospital Italiano de Buenos Aires, Argentina.
  • Cristiano E; Centro de esclerosis múltiple de Buenos Aires, Argentina.
  • Tavolini D; INECO Neurociencias Oroño - Rosario, Argentina.
  • Nadur D; Hospital Naval - Hospital de Clínicas, Buenos Aires, Argentina.
  • Granda AMT; Hospital José Carrasco Arteaga, Ecuador.
  • Weiser R; Hospital Horacio Oduber, Aruba.
  • Cassará FP; Hospital Universitario Austral, Buenos Aires, Argentina; Fundación Favaloro, Buenos Aires, Argentina.
  • Sinay V; Fundación Favaloro, Buenos Aires, Argentina.
  • Rodríguez CC; Universidad Catolica de Chile, Chile.
  • Lazaro LG; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina.
  • Menichini ML; Sanatorio Británico de Rosario, Argentina.
  • Piedrabuena R; Clinica Reina Fabiola, Córdoba, Argentina; Instituto Lennox, Córdoba, Argentina.
  • Escobar GO; Hosp.Patrocinio P.Ruiz,San Cristóbal, Venezuela.
  • Carrá A; Hospital Británico de Buenos Aires, Argentina.
  • Chertcoff A; Hospital Británico de Buenos Aires, Argentina.
  • Pujols BS; Hospital Regional Universitario José Ma Cabral y Báez.
  • Vrech C; Sanatorio Allende, Córdoba, Argentina.
  • Tarulla A; Hospital de Agudos P. Piñero, Buenos Aires, Argentina.
  • Carvajal R; Hospital Universitario Nacional de Colombia.
  • Mainella C; Hospital Español de Rosario, Argentina.
  • Becker J; Hospital São Lucas - Pontifícia Universidade Católica do Rio Grande do Sul, Brazil.
  • Peeters LM; University Multiple Sclerosis Center; Biomedical Research Institute & Data Science Institute, Hasselt University, Belgium.
Mult Scler Relat Disord ; 51: 102886, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1118600
ABSTRACT

BACKGROUND:

There is no data regarding COVID-19 in Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America.

OBJECTIVE:

The objective of this study was to describe the clinical characteristics and outcomes of patients included in RELACOEM, a LATAM registry of MS and NMOSD patients infected with COVID-19.

METHODS:

RELACOEM is a longitudinal, strictly observational registry of MS and NMOSD patients who suffer COVID-19 and Dengue in LATAM. Inclusion criteria to the registry were either (1) a biologically confirmed COVID-19 diagnosis based on a positive result of a COVID-19 polymerase chain reaction (PCR) test on a nasopharyngeal swab; or (2) COVID-19-typical symptoms (triad of cough, fever, and asthenia) in an epidemic zone of COVID-19. Descriptive statistics were performed on demographic and clinical variables. The cohort was later stratified for MS and NMOSD and univariate and multivariate logistic regression analysis was performed to identify variables associated with hospitalizations/intensive critical units (ICU) admission.

RESULTS:

145 patients were included in the registry from 15 countries and 51 treating physicians. A total of 129 (89%) were MS patients and 16 (11%) NMOSD. 81.4% patients had confirmed COVID-19 and 18.6% were suspected cases. 23 (15.8%) patients were hospitalized, 9 (6.2%) required ICU and 5 (3.4 %) died due to COVID-19. In MS patients, greater age (OR 1.17, 95% CI 1.05 - 1.25) and disease duration (OR 1.39, 95%CI 1.14-1.69) were associated with hospitalization/ICU. In NMOSD patients, a greater age (54.3 vs. 36 years, p=<0.001), increased EDSS (5.5 vs 2.9, p=0.0012) and disease duration (18.5 vs. 10.3 years, p=0.001) were significantly associated with hospitalization/ICU.

CONCLUSION:

we found that in MS patients, age and disease duration was associated with hospitalization and ICU admission requirement, while age, disease duration and EDSS was associated in NMOSD.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuromyelitis Optica / COVID-19 / Multiple Sclerosis Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2021 Document Type: Article Affiliation country: J.msard.2021.102886

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuromyelitis Optica / COVID-19 / Multiple Sclerosis Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2021 Document Type: Article Affiliation country: J.msard.2021.102886